New treatments for a severe autoimmune blood disorder
Official title: Novel approaches for the treatment of autoimmune disease
Funded at Astero Erado INC · NIH-11065901 · Data updated 2026-11-12
This study is testing a new treatment for people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) to help tackle the root cause of the condition and reduce the chances of serious complications and relapses.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Astero Erado INC NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | January 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,019,657 |
| NIH project number | 2R44AI174502-02A1 |
| Project ID | NIH-11065901 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with immune-mediated thrombotic thrombocytopenic purpura (iTTP).
✕Less likely to help
Patients with other types of autoimmune diseases or those not diagnosed with iTTP may not benefit from this research.
What this research studies
This research focuses on developing a novel therapy for immune-mediated thrombotic thrombocytopenic purpura (iTTP), a life-threatening autoimmune condition. The approach aims to address the underlying cause of iTTP, which is a deficiency of a specific protease (ADAMTS13) due to autoantibodies. By targeting these autoantibodies and improving the regulation of blood clotting factors, the research seeks to reduce the risk of severe complications and relapses associated with current treatments. Patients may be monitored for their response to this new therapeutic approach over the course of the study.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment outcomes and reduce mortality rates for patients with iTTP.
How similar studies have gone: While current treatments exist, this approach is novel and aims to improve upon existing therapies that have shown limited success.
Where this research is happening
-
Astero Erado INC
College Station, United States Active
Researchers
- Principal investigator: Kannanganat Sidharthan, Sunil — Astero Erado INC
- Study coordinator: Kannanganat Sidharthan, Sunil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.